🇪🇺 Moroctocog alfa (AF-CC) in European Union

EMA authorised Moroctocog alfa (AF-CC) on 13 April 1999

Marketing authorisation

EMA — authorised 13 April 1999

  • Application: EMEA/H/C/000232
  • Marketing authorisation holder: Pfizer Europe MA EEIG
  • Local brand name: ReFacto AF
  • Indication: Treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor-VIII deficiency). ReFacto AF is appropriate for use in adults and children of all ages, including newborns. ReFacto AF does not contain von-Willebrand factor, and hence is not indicated in von-Willebrand's disease.
  • Status: approved

Read official source →

Other Hematology approved in European Union

Frequently asked questions

Is Moroctocog alfa (AF-CC) approved in European Union?

Yes. EMA authorised it on 13 April 1999.

Who is the marketing authorisation holder for Moroctocog alfa (AF-CC) in European Union?

Pfizer Europe MA EEIG holds the EU marketing authorisation.